JAMA Surgery: New Study Confirms the Diagnostic Power of DEX-G2
At Cizzle Bio, our goal is simple but urgent: detect cancer earlier, when treatment is most effective. That mission was further advanced by a major clinical study featured in JAMA Surgery and detailed in our latest press release. The study confirms the diagnostic performance of DEX-G2, Cizzle Bio’s biomarker-based blood test for earlier gastric cancer detection.
The DESTINEX study evaluated the biomarker signature that forms the foundation of DEX-G2. Its findings validate the clinical performance of DEX-G2 as a minimally invasive, highly accurate tool to detect early gastric cancer—the third deadliest cancer globally.
What the Study Found
Researchers analyzed 809 blood samples from 480 individuals, including patients with gastric cancer and matched controls. The study was conducted at leading medical centers in Japan and South Korea.
Using a panel of microRNAs derived from exosomes and cell-free serum, refined through machine learning, the study demonstrated that:
DEX-G2 achieved 95 percent sensitivity for detecting early-stage gastric cancer
It reached a diagnostic accuracy of 96.8 percent (area under the curve)
It maintained strong performance across different tumor stages and patient subgroups
Biomarker levels dropped significantly after tumor removal, confirming tumor specificity
These results support DEX-G2 as a minimally invasive tool that can help detect gastric cancer at an earlier, more treatable stage.
Why It Matters for Patients
Gastric cancer remains one of the deadliest cancers worldwide, largely because it is often diagnosed too late. Many people have no symptoms in the early stages. Others face barriers to screening, especially in areas where procedures like endoscopy are not widely available.
DEX-G2 offers a potential alternative. Unlike imaging or invasive diagnostics, it is a minimally invasive blood test that may be easier to integrate into routine care. It is designed to detect cancer earlier, when more treatment options are available and outcomes can be significantly improved.
Where We Go From Here
With this validation now published and detailed in our press release, Cizzle Bio is preparing DEX-G2 for clinical use through CLIA-certified laboratories, which will allow providers to begin offering the test to patients.
Cizzle Bio holds exclusive global rights to DEX-G2 and is committed to bringing this innovation to patients in the United States and internationally. Our focus is on ensuring scientific integrity while delivering real-world solutions that improve access to early detection.
Building a Future of Earlier Answers
This study represents a significant milestone, but it is only one step forward. At Cizzle Bio, we are building a platform of minimally invasive diagnostics that support patients and their care teams with earlier answers and better outcomes.
We believe that early detection changes everything. And with DEX-G2, that belief is now reinforced by science, supported by clinical data, and moving into practice.
Follow us @cizzlebio for updates on innovation, access, and patient-centered progress.
